What Medicare Actually Covers for a GLP-1, and the Bridge That Sits Outside It

Answer first: the indication decides everything

Medicare Part D cannot cover a GLP-1 prescribed for weight loss. That is not a formulary decision your plan made, and appealing it will not move it, because the exclusion is in the statute that defines what a Part D drug is.

The same molecule prescribed for a different approved condition is a different question entirely. CMS states that type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic MASH with moderate to advanced liver fibrosis are eligible for Part D coverage.

So the first thing to establish is not which drug you want. It is which indication your prescriber is treating, because that single fact decides whether Part D is even in play.

For weight loss alone, there is now a temporary federal demonstration called the Medicare GLP-1 Bridge. It is running through the end of 2027, and it works by sitting outside Part D rather than inside it.

Where the rule actually comes from

The chain runs through two sections of federal law and it is short. Part D's definition of a covered drug excludes anything that may be excluded or restricted under the Medicaid drug provisions, with a handful of named exceptions for smoking cessation agents, certain barbiturates and benzodiazepines.

The Medicaid provision it points to lists what states may exclude. Its first item is agents when used for anorexia, weight loss, or weight gain.

Weight loss is not among the exceptions Part D carved back in. That is the whole mechanism, and it explains why the answer has been so consistent across plans that otherwise differ on everything.

Notice the wording. The statute excludes agents when used for a purpose, not agents by name. A drug is not permanently outside Part D; a use is. That is why the indication question is the one that matters.

The same list governs Medicaid, and there it is permissive rather than mandatory. States may exclude these agents, which means some do and some do not, and the answer is a state-by-state one rather than a federal one.

The Bridge, and what it deliberately is not

CMS describes the Medicare GLP-1 Bridge as a short-term demonstration providing eligible Part D beneficiaries with access to certain GLP-1 drugs. It began in July 2026 and runs through the end of 2027.

The structural point is that it operates outside the Part D benefit's coverage and payment flow. Part D sponsors carry no risk for drugs furnished under it, and they do not have to opt in for an eligible beneficiary to use it.

CMS is running it through a single central processor that handles prior authorization, claims adjudication and payment to pharmacies. The agency named Humana, the administrator of the Limited Income Newly Eligible Transition program, for that role.

The legal authority is demonstration authority, not a change to the coverage rules. CMS cites the Secretary's power to test whether changes in methods of payment or reimbursement would increase the efficiency and economy of health services under Medicare.

A related model called BALANCE, which would have let Part D plans opt into covering these drugs for weight management, is not launching in 2027. CMS extended the Bridge instead and says it will use the period to collect utilization data.

Who qualifies, in CMS's own terms

Eligibility rests on a prior authorization request in which a provider attests to specific criteria. The prescription must be to reduce excess body weight and maintain weight reduction, in combination with ongoing lifestyle modification including structured nutrition and physical activity.

The clinical thresholds come in three tiers, all for adults 18 and over. A BMI of 35 or higher qualifies on its own.

A BMI of 30 or higher qualifies with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or above. A BMI of 27 or higher qualifies with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.

The demonstration is nationwide, covering all states and territories. It reaches standalone drug plans, Medicare Advantage plans with drug coverage, Special Needs Plans, employer group waiver plans, and the Limited Income Newly Eligible Transition program.

Once approved, the authorization is durable. Medicare states it is valid through the end of 2027 including refills and dose changes, unless you switch to a different GLP-1.

Two disqualifications that surprise people

The first is having a condition Part D already covers. If you have type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH with moderate to advanced fibrosis, you are not eligible for the Bridge.

That holds even if your own plan does not actually cover a GLP-1 for that condition. CMS says so explicitly, and directs those requests back through the plan's formulary exception process rather than into the demonstration.

CMS also says it will monitor plan formulary and utilization management practices to make sure plans do not shift coverage decisions from Part D into the Bridge. The demonstration does not modify appeal rights or exception requests.

The second disqualification is prior use. A beneficiary who already filled a GLP-1 through their Part D plan during 2026 is not eligible for the Bridge that year.

CMS reviews its own claims data to determine this, across a named list of GLP-1 products. If you are ruled out on that basis, the pharmacy receives a notification and can tell you.

What the Bridge does not do to your Part D math

Because the demonstration sits outside the benefit, none of it counts toward the numbers your plan tracks. The Part D deductible does not apply to these fills.

No part of the copay counts toward your true out-of-pocket costs. That is the running total that moves you through the phases of the Part D benefit, so a year of Bridge fills leaves it untouched.

Low-income subsidies do not apply to any portion of the copay either, and the copay stays the same regardless of which phase of the Part D benefit you happen to be in.

Discounts cannot be layered on top. CMS states that coupons and discount programs may not be applied to Bridge claims, and that the demonstration is the primary payer and will not coordinate benefits with other payers.

None of that makes it a bad deal. It makes it a parallel track, and worth understanding as one rather than as an improvement to your existing coverage.

Which products are on it, and which are not

CMS publishes the list, and it is narrower than the category. As of the current list, an eligible drug is Foundayo, Wegovy in both injection and tablet form, or Zepbound in the KwikPen presentation, when used to reduce excess body weight and maintain weight reduction.

The presentation qualifier is doing real work there. CMS states that the single-dose vial and single-dose pen presentations of Zepbound are not available through the demonstration, and it publishes the specific product codes.

The list has already changed once. CMS updated it in April 2026 to add Foundayo following that product's approval, and to clarify the Zepbound presentation limit. The agency says the list may be updated again during the demonstration.

Compounded products are a separate question and are not part of this. The demonstration is a payment arrangement with participating manufacturers for named, approved products.

Medicaid is fifty answers, not one

The federal statute lets a state exclude or otherwise restrict agents used for weight loss. It does not require the exclusion, which is why Medicaid coverage of these drugs varies so widely.

That makes the useful question local rather than national. Your state's Medicaid program publishes its own drug list and its own criteria, and that document is the answer for you.

Where a state does cover them, prior authorization and step requirements are common, and the mechanics look like the commercial ones this site describes elsewhere.

Manufacturer savings cards are not a workaround. Every one of them excludes people enrolled in Medicaid and other government-funded programs, by name, on the enrollment form.

What to establish, in order

Start with the indication your prescriber is treating and get it in writing. If it is one Part D covers, the route is your plan, and a denial there is appealable through the ordinary process.

If the prescription is for weight reduction alone, the Bridge is the current federal route, and Medicare publishes an eligibility questionnaire and a phone line for it.

Check whether you have already filled a GLP-1 under your plan this year, because that is the disqualification people do not see coming. Your plan's claims history is where that answer lives.

Then compare against cash channels honestly. Money spent outside a plan generally earns no credit toward a deductible or an out-of-pocket maximum, and Medicare says as much about discount cards in its own guidance.